Abstract
Patient adherence to many osteoporosis treatments, primarily bisphosphonates, is generally poor, thus leading to a significant reduction in antifracture efficacy. Patient perceptions about the necessity of the prescribed medication to treat osteoporosis and the concerns about the potential adverse effects are important and potentially modifiable determinants of adherence, in addition to other factors, such as difficult dosing regimens and high dosing frequency. Denosumab (Dmab) is a fully human monoclonal antibody against the receptor activator of nuclear factor-κB ligand (RANKL), which, through the prevention of the RANKL/RANK interaction, inhibits osteoclast-mediated bone resorption and significantly reduces the risk of vertebral, nonvertebral, and hip fractures. It is administered subcutaneously every 6 months for the treatment of postmenopausal osteoporosis. Preference and adherence to Dmab treatment were assessed in various clinical trials. Although with some limitations, available data suggest that Dmab is preferred to bisphosphonates, produces greater satisfaction than bisphosphonates, and would be preferentially chosen for long-term treatment. Moreover, patient perceptions about the necessity of Dmab treatment clearly outweigh the concerns about the injections, and positive beliefs about treatment positively influence medication-taking behavior. According to these data, Dmab may represent a reasonable alternative to bisphosphonates, particularly for osteoporotic women in whom a suboptimal or even poor adherence to oral treatments is expected.
| Original language | English |
|---|---|
| Pages (from-to) | 833-839 |
| Number of pages | 7 |
| Journal | International Journal of Women's Health |
| Volume | 7 |
| DOIs | |
| Publication status | Published - Oct 13 2015 |
Fingerprint
Keywords
- Denosumab
- Osteoporosis treatment
- Preference
- RANKL
ASJC Scopus subject areas
- Obstetrics and Gynaecology
- Oncology
- Maternity and Midwifery
Cite this
Update on denosumab in the management of postmenopausal osteoporosis : Patient preference and adherence. / Cairoli, Elisa; Eller-Vainicher, Cristina; Chiodini, Iacopo.
In: International Journal of Women's Health, Vol. 7, 13.10.2015, p. 833-839.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Update on denosumab in the management of postmenopausal osteoporosis
T2 - Patient preference and adherence
AU - Cairoli, Elisa
AU - Eller-Vainicher, Cristina
AU - Chiodini, Iacopo
PY - 2015/10/13
Y1 - 2015/10/13
N2 - Patient adherence to many osteoporosis treatments, primarily bisphosphonates, is generally poor, thus leading to a significant reduction in antifracture efficacy. Patient perceptions about the necessity of the prescribed medication to treat osteoporosis and the concerns about the potential adverse effects are important and potentially modifiable determinants of adherence, in addition to other factors, such as difficult dosing regimens and high dosing frequency. Denosumab (Dmab) is a fully human monoclonal antibody against the receptor activator of nuclear factor-κB ligand (RANKL), which, through the prevention of the RANKL/RANK interaction, inhibits osteoclast-mediated bone resorption and significantly reduces the risk of vertebral, nonvertebral, and hip fractures. It is administered subcutaneously every 6 months for the treatment of postmenopausal osteoporosis. Preference and adherence to Dmab treatment were assessed in various clinical trials. Although with some limitations, available data suggest that Dmab is preferred to bisphosphonates, produces greater satisfaction than bisphosphonates, and would be preferentially chosen for long-term treatment. Moreover, patient perceptions about the necessity of Dmab treatment clearly outweigh the concerns about the injections, and positive beliefs about treatment positively influence medication-taking behavior. According to these data, Dmab may represent a reasonable alternative to bisphosphonates, particularly for osteoporotic women in whom a suboptimal or even poor adherence to oral treatments is expected.
AB - Patient adherence to many osteoporosis treatments, primarily bisphosphonates, is generally poor, thus leading to a significant reduction in antifracture efficacy. Patient perceptions about the necessity of the prescribed medication to treat osteoporosis and the concerns about the potential adverse effects are important and potentially modifiable determinants of adherence, in addition to other factors, such as difficult dosing regimens and high dosing frequency. Denosumab (Dmab) is a fully human monoclonal antibody against the receptor activator of nuclear factor-κB ligand (RANKL), which, through the prevention of the RANKL/RANK interaction, inhibits osteoclast-mediated bone resorption and significantly reduces the risk of vertebral, nonvertebral, and hip fractures. It is administered subcutaneously every 6 months for the treatment of postmenopausal osteoporosis. Preference and adherence to Dmab treatment were assessed in various clinical trials. Although with some limitations, available data suggest that Dmab is preferred to bisphosphonates, produces greater satisfaction than bisphosphonates, and would be preferentially chosen for long-term treatment. Moreover, patient perceptions about the necessity of Dmab treatment clearly outweigh the concerns about the injections, and positive beliefs about treatment positively influence medication-taking behavior. According to these data, Dmab may represent a reasonable alternative to bisphosphonates, particularly for osteoporotic women in whom a suboptimal or even poor adherence to oral treatments is expected.
KW - Denosumab
KW - Osteoporosis treatment
KW - Preference
KW - RANKL
UR - http://www.scopus.com/inward/record.url?scp=84945183036&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84945183036&partnerID=8YFLogxK
U2 - 10.2147/IJWH.S75681
DO - 10.2147/IJWH.S75681
M3 - Article
AN - SCOPUS:84945183036
VL - 7
SP - 833
EP - 839
JO - International Journal of Women's Health
JF - International Journal of Women's Health
SN - 1179-1411
ER -